Medicine type
A serotonin-modulating medicine, not a PDE5 inhibitor
Low-desire treatment guide
Flibanserin
Flibanserin, sold as Addyi in the US, is a daily medicine for a specific diagnosis—not a general libido booster or an on-demand alternative to sildenafil.
The diagnosis is narrower than the nickname
The current FDA label indicates Addyi for women under 65 with acquired, generalized hypoactive sexual desire disorder (HSDD) when low desire causes marked distress or interpersonal difficulty and is not due to another condition, relationship problems, medication or another substance.
That definition matters. Flibanserin is not indicated to enhance sexual performance, and it should not turn every period of low desire into a medical diagnosis. Its average benefit in trials was modest, while the risks and interactions require a proper medication review.
Flibanserin at a glance
What is established—and what the label limits.
FDA indication
Acquired, generalized HSDD in women under 65
Use pattern
A daily bedtime medicine, not an on-demand product
Review point
The current label says to stop after 8 weeks if symptoms do not improve
Average benefit
Modest in the approval trials
Not indicated for
Sexual performance enhancement or use in men
Flibanserin and Lovegra answer different questions
| Flibanserin (Addyi) | Lovegra (sildenafil) | |
|---|---|---|
| Active ingredient | Flibanserin 100 mg | Sildenafil 100 mg pack claim |
| Main target | A narrowly defined low-desire disorder | Physical blood-flow response during stimulation |
| Use pattern | Daily, at bedtime | Marketed as on-demand |
| US regulatory context | FDA-approved for a narrow HSDD indication in women under 65 | Not FDA-approved for female sexual dysfunction |
| Evidence summary | Modest average benefit in the indicated group | Mixed results in women; possible benefit in narrower subgroups |
| Key reading question | Does the full HSDD definition fit? | Is the concern physical arousal rather than desire? |
Flibanserin questions
Is flibanserin female Viagra?
No. Flibanserin is a daily medicine for a narrowly defined low-desire disorder. Sildenafil is an on-demand blood-flow medicine and is not FDA-approved for female sexual dysfunction.
Does it work for every kind of low desire?
No. The FDA indication excludes low desire explained by another condition, relationship problems, medication or another substance. The average trial benefit was modest.
Must someone taking Addyi avoid alcohol completely?
The current US label uses specific timing and drink-count instructions rather than blanket lifetime abstinence. Because the interaction can cause severe low blood pressure and fainting, a prescriber should explain the instructions for the individual patient.
How long is it tried?
The current FDA label says to discontinue after 8 weeks if HSDD symptoms have not improved.
Is it available in Singapore?
Current registration must be checked against HSA's public register for the exact product. A foreign approval or online listing does not establish Singapore registration.
Sources
- FDA: Addyi prescribing information (2025)
Current indication, alcohol timing, contraindications, adverse reactions and eight-week review point.
- HSA Singapore: register of therapeutic products
Official place to check the exact product's current registration.
Start with the symptom, not the product name
Desire and physical arousal are not interchangeable. Compare the questions each medicine is designed—or marketed—to answer.
Content and sources reviewed